Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

133%(4 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_2

50%

Ph phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Detailed Status

Completed3

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (50.0%)

Phase 22 (50.0%)

Trials by Status

terminated125%

completed375%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_2

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

NCT03070392

completedphase_1

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

NCT02570308

terminatedphase_2

IMCgp100-401 Rollover Study

NCT02889861

completedphase_1

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

NCT01211262

Clinical Trials (4)

Showing 4 of 4 trials

NCT03070392Phase 2

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Completed

NCT02570308Phase 1

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Completed

NCT02889861Phase 2

IMCgp100-401 Rollover Study

Terminated

NCT01211262Phase 1

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Completed

All 4 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 4